**An FDA advisory committee's July 2026 vote provides the main recent catalyst for trader sentiment on BPC-157 reaching Category 1 status.** The Pharmacy Compounding Advisory Committee recommended 8-6-1 adding both the free base and acetate forms to the 503A Bulks List despite FDA staff objections citing insufficient human safety and efficacy data, primarily from preclinical studies. Removal from Category 2 in April 2026 lifted prior restrictions but did not authorize compounding or confer Category 1 placement. Any final move requires formal notice-and-comment rulemaking, a multi-month process that typically spans 8–24 months even after a favorable recommendation. Limited clinical evidence and the non-binding nature of the advisory vote continue to shape assessments of near-term resolution timelines.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtMỚI
Dec 31, 2026
December 31, 2026
41%
$4,143 KL.
December 31, 2026
$2,141 KL.
41%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**An FDA advisory committee's July 2026 vote provides the main recent catalyst for trader sentiment on BPC-157 reaching Category 1 status.** The Pharmacy Compounding Advisory Committee recommended 8-6-1 adding both the free base and acetate forms to the 503A Bulks List despite FDA staff objections citing insufficient human safety and efficacy data, primarily from preclinical studies. Removal from Category 2 in April 2026 lifted prior restrictions but did not authorize compounding or confer Category 1 placement. Any final move requires formal notice-and-comment rulemaking, a multi-month process that typically spans 8–24 months even after a favorable recommendation. Limited clinical evidence and the non-binding nature of the advisory vote continue to shape assessments of near-term resolution timelines.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Thị trường mở: Jun 22, 2026, 10:10 PM ET
Khối lượng
$4,143Ngày kết thúc
Jan 1, 2027Thị trường mở
Jun 22, 2026, 10:10 PM ETNgười giải quyết
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**An FDA advisory committee's July 2026 vote provides the main recent catalyst for trader sentiment on BPC-157 reaching Category 1 status.** The Pharmacy Compounding Advisory Committee recommended 8-6-1 adding both the free base and acetate forms to the 503A Bulks List despite FDA staff objections citing insufficient human safety and efficacy data, primarily from preclinical studies. Removal from Category 2 in April 2026 lifted prior restrictions but did not authorize compounding or confer Category 1 placement. Any final move requires formal notice-and-comment rulemaking, a multi-month process that typically spans 8–24 months even after a favorable recommendation. Limited clinical evidence and the non-binding nature of the advisory vote continue to shape assessments of near-term resolution timelines.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Khối lượng
$4,143Ngày kết thúc
Jan 1, 2027Thị trường mở
Jun 22, 2026, 10:10 PM ETNgười giải quyết
0x65070BE91...**An FDA advisory committee's July 2026 vote provides the main recent catalyst for trader sentiment on BPC-157 reaching Category 1 status.** The Pharmacy Compounding Advisory Committee recommended 8-6-1 adding both the free base and acetate forms to the 503A Bulks List despite FDA staff objections citing insufficient human safety and efficacy data, primarily from preclinical studies. Removal from Category 2 in April 2026 lifted prior restrictions but did not authorize compounding or confer Category 1 placement. Any final move requires formal notice-and-comment rulemaking, a multi-month process that typically spans 8–24 months even after a favorable recommendation. Limited clinical evidence and the non-binding nature of the advisory vote continue to shape assessments of near-term resolution timelines.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp